ArticleEmerging infectious diseases2016
Shigella Antimicrobial Drug Resistance Mechanisms, 2004-2014.
Article in Emerging infectious diseases, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed, 55 citations in OpenAlex.
- Review
- Genomic insights into Shigella species isolated from small ruminants and manure in the North West Province, South Africa.Applied microbiology and biotechnology · 2025Article
- Multidrug-resistant conjugative plasmid carrying mphA confers increased antimicrobial resistance in Shigella.Scientific reports · 2024Article
- Prevalence and changing antimicrobial resistance profiles of Shigella spp. isolated from diarrheal patients in Kolkata during 2011-2019.PLoS neglected tropical diseases · 2024Article
- Anti-virulence and bactericidal activities of Stattic againstApplied and environmental microbiology · 2023Article
- Increasing trend of antibiotic resistance in Shigella in Bangladesh: a plasmid-mediated transfer of mphA macrolide resistance gene.Research square · 2023Article
- Prevalence and antimicrobial susceptibility pattern ofIranian journal of microbiology · 2023Article
- A Shigella sonnei clone with extensive drug resistance associated with waterborne outbreaks in China.Nature communications · 2022Article
- High frequency of antimicrobial resistance and virulence gene in Shigella species isolated from pediatric patients in an Iranian Referral Hospital.Acta bio-medica : Atenei Parmensis · 2022Article
- Antimicrobial resistance in shigellosis: A surveillance study among urban and rural children over 20 years in Bangladesh.PloS one · 2022Article
- Draft Genome Sequences of Multidrug-ResistantMicrobiology resource announcements · 2021Article
- Update onAntimicrobial agents and chemotherapy · 2021Article
- Whole genome sequence analysis ofMicrobial genomics · 2021Article
- Rapid Increase of CTX-M-Producing Shigella sonnei Isolates in Switzerland Due to Spread of Common Plasmids and International Clones.Antimicrobial agents and chemotherapy · 2020Article
- Shigella flexneri: an emerging pathogen.Folia microbiologica · 2020Review
- Resistance of Gram-Negative Bacteria to Current Antibacterial Agents and Approaches to Resolve It.Molecules (Basel, Switzerland) · 2020Review
- Commensal Escherichia coli are a reservoir for the transfer of XDR plasmids into epidemic fluoroquinolone-resistant Shigella sonnei.Nature microbiology · 2020Observational
- A Phage Therapy Guide for Clinicians and Basic Scientists: Background and Highlighting Applications for Developing Countries.Frontiers in microbiology · 2020Review
- Virulence gene profiles ofPathogens and global health · 2019Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
To determine antimicrobial drug resistance mechanisms of Shigella spp., we analyzed 344 isolates collected in Switzerland during 2004-2014. Overall, 78.5% of isolates were multidrug resistant; 10.5% were ciprofloxacin resistant; and 2% harbored mph(A), a plasmid-mediated gene that confers reduced susceptibility to azithromycin, a last-resort antimicrobial agent for shigellosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.